A 73-year-old woman presented for her glaucoma progress evaluation. She had been diagnosed with primary open-angle glaucoma (OAG) four years earlier and started on latanoprost 0.005% in each eye, which she tolerated well. She was 20/25 OU and her vision was commensurate with her mild cataracts.
Her visual fields showed very mild loss OD and a moderately extensive inferior arcuate defect OS. Recent visual field analysis confirmed no changes in either eye. Central corneal thickness was 562µm OD and 568µm OS. Intraocular pressures (IOPs) were 19mm Hg OU. Her best IOP reduction from latanoprost was 15mm Hg OD and 17mm Hg OS.
A 54-year-old Hispanic male presented with complaints of blurred vision in his right eye for the past month. The patient has never had eye problems in the past and has always enjoyed good vision.
Find our more about this case in our most recent Retina Quiz.
Q: What is the real significance of endothelial blebs and how do I best view them in my scleral lens wearers?
Find out in our most recent Cornea + Contact Lens Q + A.
A notable addition to TFOS DEWS II is a report on iatrogenic dry eye. Not a subject covered in the original DEWS report, it was time to acknowledge “the number of cases of dry eye that are caused by medical examination or treatment such as topical medications, systemic drugs, ophthalmic surgical procedures and even cosmetic procedures,” says James S. Wolffsohn, PhD, a member of the DEWS II iatrogenic subcommittee and harmonizer for the report. This article discusses the new findings in iatrogenic dry eye and how you can use them to better serve your patients.
Anti-vascular endothelial growth factor (VEGF) therapy has dramatically revolutionized the management of age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusions. Many trials have shown that, worldwide, the treatment has significantly changed outcomes in patients with retinal vascular disease and reduced the incidence of blindness from these conditions. In each of these indications, the best outcomes have been shown with fixed dosing schedules. However, such a regimen risks either over- or undertreatment if the chosen intervals between treatments are too short or too long.
New technologies that could extend the duration between treatments could offer a significant benefit to patients by reducing the burden of treatment while improving vision.